Company name:

Portola Pharmaceuticals Inc

  • IPO SHARE PRICE:
    $14.00
  • IPO DATE:
    May 22, 2013
  • TICKER:
    PTLA
  • MAIN STOCK EXCHANGE:
    NASDAQ
  • CURRENT HQ LOCATION:
    270 E Grand Avenue South San Francisco California 94080
  • FISCAL YEAR END:
    December 31
  • INCORPORATION JURISDICTION:
    DE
  • ORGANIZED AS THE FOLLOWING LEGAL TYPE:
    Corporation
  • Investor Relations Webpage:
    Coming soon!
  • TAX RATE:
    USA federal corporate nominal income tax rate is 21%

Short Description

Portola Pharmaceuticals Inc

We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com

Statement of Cash Flow

Quarterly Annual
(USD in thousand)
Selected Year:
31-Dec
2019
OPERATING ACTIVITIES
Cash received and spent on operating activites of business — buying materials, paying salaries, receiving payments from clients, etc
13.6% - Stock-based compensation
7.1% - Loss on excess and obsolete inventory of Bevyxxa asset group
6.6% - Interest expense
4.6% - Accrued and other liabilities
1.6% - Unbilled - collaboration and license revenue
1.1% - Provision for excess and obsolete inventory
0.8% - Operating lease right-of-use asset amortization
0.8% - Impairment of SRX intangible asset
0.8% - Depreciation and amortization
0.1% - Other
SOURCEs
62.9% 6.6% 4.6% 7.1% 13.6%
100 %
0%
USES
3.4% 15.3% 76.2%
76.2% - Net income (loss)
15.3% - Inventory
3.4% - Notes payable and long-term royalty-based debt
2.0% - Accounts receivable
1.0% - Prepaid and other assets
0.8% - (Gain) loss on derivative
0.7% - Accounts payable
0.3% - (Accretion) amortization of investment discount premium net
0.2% - Accrued research and development
0.1% - Deferred revenue
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Net income (loss)
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 ($285,620) ($350,544) ($292,876) ($283,551) ($275,084)
Depreciation and amortization
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 2,410 3,102 3,000 2,846 2,552
Operating lease right-of-use asset amortization
-
-
-
-
-
-
 - - 3,224 3,224 -
Amortization of (discount) premium on investments
$45,679
$45,679
$45,679
$45,679
-
-
 - - - - -
Stock-based compensation
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 43,284 9,201 52,075 43,661 37,920
Provision for excess and obsolete inventory
-
-
-
-
-
$45,679
 - 2,246 4,152 2,317 8,440
Loss on excess and obsolete inventory of Bevyxxa asset group Loss on excess and obsolete inventory of Bevyxxa asset group
-
-
-
-
-
-
 - - 27,451 27,451 -
(Accretion) amortization of investment discount premium net (Accretion) amortization of investment discount premium net
-
-
-
-
$45,679
$45,679
 (235) (1,864) (1,225) (1,102) (556)
Interest expense
$45,679
-
-
$45,679
$45,679
$45,679
 11,603 18,740 25,371 23,956 20,264
Impairment of SRX intangible asset
-
-
-
-
-
-
 - - 3,151 3,151 -
Charge associated with our Gen 1 manufacturing process transition Charge associated with our Gen 1 manufacturing process transition
-
-
-
-
-
$45,679
 - 10,311 - - -
(Gain) loss on sale of assets
-
-
-
-
$45,679
$45,679
 52 15 - - -
(Gain) loss on derivative
-
-
-
-
$45,679
$45,679
 4,562 (6,357) (2,931) 710 12,676
Unrealized (gain) loss on foreign currency forward contracts Unrealized (gain) loss on foreign currency forward contracts
$45,679
$45,679
$45,679
$45,679
-
-
 - - - - -
Change in fair value of convertible preferred stock warrant liability Change in fair value of convertible preferred stock warrant liability
$45,679
$45,679
$45,679
-
-
-
 - - - - -
Reserve for uncertain tax positions
-
-
$45,679
$45,679
$45,679
-
 - - - - -
Unbilled - collaboration and license revenue
-
-
-
-
-
$45,679
 - (3,186) 6,097 2,909 1,500
Accounts receivable
-
-
-
-
-
$45,679
 (3,750) 607 (7,698) 4,377 24,548
Receivables from collaborators
$45,679
$45,679
$45,679
$45,679
$45,679
-
 - - - - -
Inventory
-
-
-
-
$45,679
$45,679
 (1,099) (12,612) (58,830) (75,929) (62,404)
Prepaid and other assets
-
$45,679
$45,679
$45,679
$45,679
$45,679
 (4,395) (10,968) (3,813) 10,459 12,920
Prepaid expenses and other assets
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 235 (7,496) - 1,974 -
Prepaid research and development
-
-
$45,679
$45,679
$45,679
-
 - - - - -
Other assets
$45,679
-
-
-
-
-
 - - - - -
Accounts payable
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (5,242) 1,881 (2,652) 2,422 2,340
Accrued research and development
-
-
$45,679
$45,679
$45,679
$45,679
 21,155 (25,142) (582) (1,146) (8,076)
Accrued compensation and employee benefits
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 6,720 (732) - - -
Accrued income taxes
$45,679
-
-
-
-
-
 - - - - -
Accrued and other liabilities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 1,856 4,246 17,668 4,200 (40,972)
Deferred revenue
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (15,796) (1,288) (360) (1,154) (1,964)
Notes payable long-term royalty-based debt and obligation to collaborator Notes payable long-term royalty-based debt and obligation to collaborator
-
-
-
-
-
$45,679
 - (1,412) - (11,799) -
Notes payable and long-term royalty-based debt
-
-
-
-
-
-
 - (1,412) (13,152) (16,873) (14,884)
Other
-
-
-
-
-
-
 52 - 195 195 -
Other liabilities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (865) (965) - - -
Net cash provided by (used in) operating activities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 ($225,125) ($326,058) ($237,923) ($245,388) ($284,400)
Selected Year:
31-Dec
2019
INVESTING ACTIVITIES
Cash spent on acquiring plant, equipment and other businesses, cash recei0 from sale of plant, equipment and subsidiaries as well cash parked temporarily in different securities - government bonds typically
80.3% - Maturities of investment securities
SOURCEs
19.7% 80.3%
100 %
0%
USES
99.6%
99.6% - Purchases of investment securities
0.4% - Capital expenditures
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
(Increase) decrease in restricted cash and deposits
$45,679
-
$45,679
$45,679
$45,679
-
 - - - - -
(Purchases) sale of investment securities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (575,624) (259,083) - (249,604) -
Purchases of investment securities
-
-
-
-
-
-
 - - (368,747) (415,220) (185,892)
Maturities of investment securities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 353,088 435,723 297,289 273,514 401,452
Capital expenditures
-
-
-
-
-
-
 (1,236) (2,559) (1,544) (2,180) (3,852)
(Purchase) sale of property and equipment
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (1,236) (2,559) - - -
Purchases of intangible assets
-
-
-
-
$45,679
$45,679
 (5,000) - - - -
Net cash provided by (used in) investing activities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 ($228,772) $174,081 ($73,002) ($102,178) $211,708
Selected Year:
31-Dec
2019
FINANCING ACTIVITIES
Items in this group are concerned with borrowing funds, repaying debt, issuing equity, buying back shares, etc.
62.5% - Public equity offering
31.2% - Borrowing
6.4% - Issuance of common stock under Employee Stock Purchase Plan (ESPP)
SOURCEs
31.2% 6.4% 62.5%
100 %
0%
USES
99.8%
0.2% - Payments of long-term obligation to collaborator
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Issuance of common stock
-
-
-
-
$45,679
-
 - - - - -
Public equity offering
$45,679
$45,679
$45,679
$45,679
-
-
 379,894 - 243,941 243,941 -
Issuance of convertible preferred stock
$45,679
-
-
-
-
-
 - - - - -
Issuance of common stock under Employee Stock Purchase Plan (ESPP) Issuance of common stock under Employee Stock Purchase Plan (ESPP)
-
-
$45,679
$45,679
$45,679
$45,679
 19,642 15,389 24,896 14,638 1,516
Proceeds from issuance of common stock upon exercise of stock options Proceeds from issuance of common stock upon exercise of stock options
$45,679
$45,679
-
-
-
-
 - - - - -
Offering costs
$45,679
$45,679
$45,679
$45,679
$45,679
-
 - - - - -
Borrowing (repayment) under long-term notes payable
-
-
-
$45,679
-
$45,679
 - - - - -
Repayment of debt
$45,679
-
-
-
-
-
 - - - - -
Proceeds from long-term obligation to Collaborator
-
-
-
$45,679
-
$45,679
 - - - - -
Payments of long-term obligation to collaborator
-
-
-
-
-
-
 - - (976) (1,254) (1,112)
Borrowing
-
-
-
-
$45,679
$45,679
 47,444 95,000 121,703 62,500 -
Debt issuance costs
-
-
-
-
$45,679
-
 - - - - -
Dividends to non-controlling interest
-
-
-
$45,679
-
$45,679
 - (140) - - -
Repurchases of unvested common stock
$45,679
-
-
-
-
-
 - - - - -
Net cash provided by (used in) financing activities
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 $446,980 $110,249 $389,564 $319,825 $404
Selected Year:
31-Dec
2019
NET CHANGE IN CASH
Grand Total for sum of cash flows coming from operations, investing and financing
$78,637,000
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Cash and equivalents - Beginning of period
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 $188,658 $181,741 $140,013 $526,116 $874,600
Effect of changes in foreign exchange rates on cash
-
-
-
-
-
-
 - - (2) (25) (92)
(Decrease) increase in cash and cash equivalents
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 (6,917) (41,728) 78,637 (27,766) (72,380)
Cash and equivalents - End of period
$45,679
$45,679
$45,679
$45,679
$45,679
$45,679
 $181,741 $140,013 $218,650 $409,534 $802,220